32
Participants
Start Date
October 19, 2020
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
3-[18F]Fluoro-para-hydroxyphenethylguanidine
Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG
[123I] metaiodobenzylguanidine
Single IV injection of 10.0 mCi \[123I\]MIBG
Positron emission tomography/computed tomography scan
Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of \[18F\]3F-PHPG
Planar scintigraphy scan
Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of \[123I\]MIBG
Single photon emission computed tomography/computed tomography scan
SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of \[123I\]MIBG
University of Michigan Rogel Cancer Center, Ann Arbor
University of Michigan Rogel Cancer Center
OTHER